|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 非诺贝特治疗与2型糖尿病患者长期心血管病风险的关系显示文摘2型糖尿病患者心血管病风险高,部分原因在于高三酰甘油和低高密度脂蛋白胆固醇血症。而在他汀类药物治疗基础上,加强降低三酰甘油治疗,能否降低这种风险尚不清楚。该研究的目的是在使用他汀类药物治疗的2型糖尿病患者中,确定非诺贝特能否降低心血管病风险。 | 刘莉 叶鹏 Elam MB Ginsberg HN Lovato LC Corson M Largay J Leiter LA Lopez C O'Connor PJ Sweeney ME Weiss D Friedewald WT Buse JB Gerstein HC Probstfield J Grimm R Ismail-Beigi F Goff DC Jr Fleg JL Rosenberg Y Byington RP ACCORDION study investigators | 2017 | 中华高血压杂志2017，25，6： | 7 |
| 2 | Lipid-altering efficacy and safety profile of combination therapy with ezetimiber/statin versus statin monotherapy in patients with and without diabetes:an analysis of pooled data from 27 clincal trials显示文摘 | Leiter LA Betteridge DJ Farnier M | 2011 | Diabetes Obes Metab2011，18，： | 1 |
| 3 | Willingness to pay for inhaled insulin :a contingent valuation approach显示文摘 | Sadri H MacKeigan LD Leiter LA | 2005 | Pharmacoeconomics2005，23，12： | 1 |
| 4 | Efficacy and safety of cerivastatin in primary hypercholesterolemia:a long term comparative titratin study with simvastatin显示文摘 | | 1999 | Can J Cardiol1999，15，5： | 1 |
| 5 | The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance显示文摘 | Chiasson JL Josse RG Leiter LA | 1996 | Diabetes Care1996，19，11： | 1 |
| 6 | Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANT- ATA-SU) :52 week results from a randomised, double- blind, phase 3 non-inferioritytrial 显示文摘 | Cefalu WT Leiter LA Yoon KH | 2013 | Lancet2013，382，9896： | 1 |
| 7 | Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada:results of the Dyslipidaemia International Study显示文摘 | Leiter LA Lundman P da Silva PM | 2011 | Diabet Med2011，28，11： | 1 |
| 8 | Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither显示文摘 | Conard S Bays H Leiter LA | 2010 | Diabetes Obes Metab2010，12，3： | 1 |
| 9 | Of the renin - angiotensin system and reac- tive oxygen species type 2 diabetes and angiotensin lI inhibition 显示文摘 | Leiter LA Lewanczuk RZ | 2005 | Am J Hypertens2005，18，1： | 1 |
| 10 | Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin(CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial显示文摘 | Cefalu WT Leiter LA Yoon KH | 2013 | Lancet2013，382，9896： | 1 |
| 11 | Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 Trial显示文摘 | Leiter LA Teoh H Braunwald E | 2015 | Diabetes Care2015，38，6： | 1 |
| 12 | Efficacy and safety of rosuv- astatin 40 mg versus atorvastatin 80 mg in high - risk patients with hyper- cholesterolemia: results of the POLARIS study 显示文摘 | Leiter LA Rosenson RS Stein E | 2007 | Atherosclerosis2007，194，2： | 1 |
| 13 | Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension显示文摘 | Leiter LA Cefalu WT de Bruin TW | 2014 | J Am Geriatr Soc2014，62，7： | 1 |
| 14 | Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin Ⅱ inhibition显示文摘 | Lewanczuk RZ | 2005 | Am J Hypertens2005，18，： | 1 |
| 15 | Cellular mechanism of action of metformin显示文摘 | Klip A Leiter LA | 1990 | Diabetes Cares1990，13，： | 1 |
| 16 | Effieaey and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately eontrolled with metformin ( CANTATA-SU ) : 52 week results from a randomised, double-blind, phase 3 non-inferiority trial 显示文摘 | Cefalu WT Leiter LA | 2013 | Lancet2013，382，9896： | 1 |
| 17 | Implications of recent clinical trials for the National Cholesterol Education Program AdultTreatment Panel III guidelines显示文摘 | Cheng AY Leiter LA | 2006 | Curr Opin Cardiol2006，21，4： | 1 |
| 18 | Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study显示文摘 | Leiter LA Yoon KH Arias P | 2015 | Diabetes Care2015，38，3： | 1 |
| 19 | Diabetes and cardiovascular disease:the role of glycemic control显示文摘 | Cheng AY Leiter LA | 2009 | Curr Diab Rep2009，9，： | 1 |
| 20 | Postprandial glucose regulation: new data and new implications 显示文摘 | Leiter LA Ceriello A Davidson JA | 2005 | Clin Ther2005，27，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员